Misonix (MSON) 8-K Misonix Reports First Quarter Fiscal Year 2009 Financial Results

Exhibit 99.1

For Immediate Release

Misonix Contact:	Investor Relations Contact:
Richard Zaremba	Cameron Associates, Inc.
631-694-9555	Kevin McGrath
invest@misonix.com	212-245-4577
	Kevin@cameronassoc.com

MISONIX REPORTS FIRST QUARTER FISCAL YEAR 2009 FINANCIAL RESULTS

REVENUES INCREASED 7.4%; NET INCOME OF $.05 PER DILUTED SHARE

FARMINGDALE, N.Y., November 13, 2008 —Misonix, Inc. (NASDAQ: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today reported financial results for its fiscal year 2009 first quarter ended September 30, 2008. Michael A. McManus, Jr., President and Chief Executive Officer, and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Thursday, November 13, 2008 to discuss the Company’s first quarter financial results.

• Revenues increased 7.4% to $11.3 million

• Reported net income of $320,000 or $.05 per diluted share

• The Company reported the following operational achievements:

• Entered a new, three year exclusive distribution agreement in Russia for the Sonablate 500^®

• Received second FDA approval for the Sonablate 600^® Soft Tissue Ablation System

• Entered a new two year exclusive distribution agreement in Czech Republic for Sonastar™, SonicOne^® and BoneScalpel™

Revenues for the three months ended September 30, 2008 were $11.3 million, a 7.4% increase, when compared with revenues of $10.5 million for the same period in fiscal 2008. The increase is due to a $621,000 increase in sales of laboratory and scientific products to $5.9 million and a $154,000 increase in medical device products sales to $5.4 million. The increase in sales of medical device products is due to a $173,000 increase in therapeutic medical device products partially offset by a $19,000 decrease in sales of diagnostic medical device products.

The Company reported pre-tax net income of $615,000 for the three months ended September 30, 2008 compared with a $269,000 pre-tax loss for the same period in fiscal 2008. Pre-tax income for the three months ended September 30, 2008 was positively impacted by a $1.5 million gain on the sale of the Company’s equity interest and previously written off debt in Focus Surgery, Inc.

The Company reported net income of $320,000 or $.05 per diluted share for the three months ended September 30, 2008, compared with a net loss of $226,000 or $.03 per share for the same period in fiscal 2008. Net income for the three months ended September 30, 2008 was positively impacted by the gain on the sale of the Company’s equity interest and previously written off debt in Focus Surgery, Inc.

The Company reported a backlog of unfilled orders as of September 30, 2008 of $8,164,000 compared to $7,221,000 as of September 30, 2007. Medical device products backlog was $4,361,000 and laboratory and scientific products backlog was $3,803,000.

Commenting on Misonix’s financial and operating results, Michael A. McManus, Jr., President and Chief Executive Officer, said, “We are pleased with our revenue growth and the significant progress we have made in positioning all of our business segments for growth this fiscal year. Our laboratory and scientific business, as well as our Sonora subsidiary, continued to make important contributions to our revenue growth and we are pleased with the steady improvement in their performance. The sale of our equity position in Focus Surgery strengthened our balance sheet and will enable us to focus our resources on expanding our international distribution capabilities, building customer awareness and brand equity for our medical device business and supporting opportunities in our laboratory and scientific businesses.

We have been very active in establishing new distributor agreements for our medical device products with high quality organizations that have strong track records selling high tech medical equipment. These new distributors, located primarily in Europe and South America, are expected to sell our innovative Sonastar, BoneScalpel, and SonicOne medical devices. We have also made good progress in building our new sales channel for the United States, which will ultimately consist of approximately twenty-five contract sales agents that will sell Misonix labeled product, on a commission only basis, directly to hospitals and clinics throughout the US. The SonicOne system is the first product sold by this new sales team, and, to date, we have fifteen sales agents that have completed training.

Our fee per use strategy in Europe for the Sonablate 500 is moving forward throughout the United Kingdom and European Union and we anticipate that the addition of new distribution agreements combined with an intensified sales campaign will expand SB500 utilization in Europe, making the benefits of our HIFU technology increasingly accessible to surgeons and patients alike.”

Conference Call

Misonix management will host a conference call and webcast to discuss the Company’s first quarter fiscal year 2009 financial results today, at 4:30 p.m. Eastern.

The conference call will be broadcast live via the Investor Relations section of the Company’s Web site at www.misonix.com. Alternatively, participants may join the conference call by dialing (866) 788-0543 (domestic) or (857) 350-1681 (international) and entering access code 21386797, a few minutes before the start of the call.

For those unable to attend the live results broadcasts, a recording of the live-call will be available approximately 2 hours after the event through November 20, 2008. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 80767628. The call will also be archived on the Company’s website for at least 90 days.

About Misonix:
Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

# # #

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

MISONIX, INC. And Subsidiaries
Consolidated Balance Sheets

				Derived from
				Audited Financial
	Unaudited			Statements
	September 30, 2008			June 30, 2008
Assets
Current Assets:
Cash	$	1,836,591		$	1,873,863
Accounts receivable, less allowance for doubtful accounts of $312,440 and $376,998, respectively		6,911,337			7,986,802
Inventories, net		12,319,012			12,651,564
Deferred income taxes		1,246,922			1,562,279
Prepaid expenses and other current assets		832,981			904,737
Total current assets		23,146,843			24,979,245
Property, plant and equipment, net		3,925,137			4,398,867
Deferred income taxes		952,502			1,280,217
Goodwill		5,754,120			5,784,542
Other assets		856,112			807,203
Total assets	$	34,634,714		$	37,250,074
Liabilities and stockholders’ equity
Current liabilities:
Revolving credit facilities	$	3,778,487		$	4,470,389
Notes payable		119,111			246,888
Accounts payable		4,624,174			5,497,541
Accrued expenses and other current liabilities		3,947,974			4,760,115
Current maturities of capital lease obligations		282,028			307,325
Current portion of deferred gain from sale and leaseback of building		145,024			159,195
Foreign income taxes payable		606,831			696,791
Total current liabilities		13,503,629			16,138,244
Capital lease obligations		164,232			225,909
Deferred gain from sale and leaseback of building		1,123,931			1,273,772
Deferred income taxes		246,892			250,514
Deferred income		424,039			371,452
Deferred lease liability		330,000			348,502
Total liabilities		15,792,723			18,608,393
Commitments and contingencies
Minority interest		217,184			199,237
Stockholders’ equity:
Capital stock, $0.01 par value — shares authorized 10,000,000; 7,079,169 issued, and 7,001,369 outstanding, respectively		70,792			70,792
Additional paid-in capital		25,105,564			25,052,539
Accumulated deficit		(6,310,168	)		(6,630,170	)
Accumulated other comprehensive income		171,043			361,707
Treasury stock, 77,800 shares		(412,424	)		(412,424	)
Total stockholders’ equity		18,624,807			18,442,444
Total liabilities and stockholders’ equity	$	34,634,714		$	37,250,074

MISONIX, INC. And Subsidiaries
Consolidated Statements of Operations

	Unaudited
	Three Months Ended
	September 30,
	2008			2007
Net sales	$	11,306,473		$	10,532,237
Cost of goods sold		6,881,043			5,866,443
Gross profit		4,425,430			4,665,794
Selling expenses		1,837,257			1,688,510
General and administrative expenses		2,652,805			2,505,760
Research and development expenses		776,474			710,237
Total operating expenses		5,266,536			4,904,507
Loss from operations		(841,106	)		(238,713	)
Total other income (expense)		1,472,351			(21,161	)
Income (loss) before minority interest and income taxes		631,245			(259,874	)
Minority interest in net income of consolidated subsidiaries		16,727			9,444
Income (loss) before income taxes		614,518			(269,318	)
Income tax provision (benefit)		294,516			(43,054	)
Net Income (loss)	$	320,002			($226,264	)
Net Income (loss) per share-basic	$	0.05			($0.03	)
Net income (loss) per share-diluted	$	0.05			($0.03	)
Weighted average common shares-basic		7,001,369			7,001,369
Weighted average common shares-diluted		7,031,953			7,001,369